nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—ABCB1—Progesterone—uterine cancer	0.0466	0.393	CbGbCtD
Carfilzomib—ABCB1—Dactinomycin—uterine cancer	0.0369	0.311	CbGbCtD
Carfilzomib—PSMB1—oviduct—uterine cancer	0.0224	0.083	CbGeAlD
Carfilzomib—ABCB1—Etoposide—uterine cancer	0.0208	0.176	CbGbCtD
Carfilzomib—ABCB1—Doxorubicin—uterine cancer	0.0142	0.12	CbGbCtD
Carfilzomib—PSMB8—myometrium—uterine cancer	0.00926	0.0344	CbGeAlD
Carfilzomib—PSMB10—female reproductive system—uterine cancer	0.00838	0.0311	CbGeAlD
Carfilzomib—PSMB5—myometrium—uterine cancer	0.00818	0.0304	CbGeAlD
Carfilzomib—Multi-organ failure—Dactinomycin—uterine cancer	0.00779	0.0303	CcSEcCtD
Carfilzomib—PSMB10—female gonad—uterine cancer	0.00763	0.0283	CbGeAlD
Carfilzomib—PSMB8—uterine cervix—uterine cancer	0.00721	0.0268	CbGeAlD
Carfilzomib—PSMB1—myometrium—uterine cancer	0.00715	0.0266	CbGeAlD
Carfilzomib—PSMB2—myometrium—uterine cancer	0.00698	0.0259	CbGeAlD
Carfilzomib—PSMB8—decidua—uterine cancer	0.00687	0.0255	CbGeAlD
Carfilzomib—PSMB8—endometrium—uterine cancer	0.00652	0.0242	CbGeAlD
Carfilzomib—PSMB5—uterine cervix—uterine cancer	0.00637	0.0237	CbGeAlD
Carfilzomib—PSMB8—mammalian vulva—uterine cancer	0.00631	0.0234	CbGeAlD
Carfilzomib—PSMB5—smooth muscle tissue—uterine cancer	0.00619	0.023	CbGeAlD
Carfilzomib—PSMB5—decidua—uterine cancer	0.00607	0.0225	CbGeAlD
Carfilzomib—PSMB5—endometrium—uterine cancer	0.00576	0.0214	CbGeAlD
Carfilzomib—Peripheral motor neuropathy—Epirubicin—uterine cancer	0.00564	0.0219	CcSEcCtD
Carfilzomib—PSMB5—mammalian vulva—uterine cancer	0.00557	0.0207	CbGeAlD
Carfilzomib—PSMB1—uterine cervix—uterine cancer	0.00557	0.0207	CbGeAlD
Carfilzomib—PSMB2—uterine cervix—uterine cancer	0.00543	0.0202	CbGeAlD
Carfilzomib—PSMB1—smooth muscle tissue—uterine cancer	0.00541	0.0201	CbGeAlD
Carfilzomib—PSMB5—uterus—uterine cancer	0.00531	0.0197	CbGeAlD
Carfilzomib—PSMB1—decidua—uterine cancer	0.0053	0.0197	CbGeAlD
Carfilzomib—PSMB2—smooth muscle tissue—uterine cancer	0.00528	0.0196	CbGeAlD
Carfilzomib—Peripheral motor neuropathy—Doxorubicin—uterine cancer	0.00522	0.0203	CcSEcCtD
Carfilzomib—PSMB1—renal system—uterine cancer	0.00521	0.0193	CbGeAlD
Carfilzomib—PSMB2—decidua—uterine cancer	0.00517	0.0192	CbGeAlD
Carfilzomib—PSMB2—renal system—uterine cancer	0.00508	0.0189	CbGeAlD
Carfilzomib—PSMB1—endometrium—uterine cancer	0.00503	0.0187	CbGeAlD
Carfilzomib—PSMB8—female gonad—uterine cancer	0.00492	0.0183	CbGeAlD
Carfilzomib—PSMB2—endometrium—uterine cancer	0.00491	0.0182	CbGeAlD
Carfilzomib—PSMB10—lymph node—uterine cancer	0.0049	0.0182	CbGeAlD
Carfilzomib—PSMB8—vagina—uterine cancer	0.00489	0.0181	CbGeAlD
Carfilzomib—PSMB1—mammalian vulva—uterine cancer	0.00487	0.0181	CbGeAlD
Carfilzomib—Neuritis—Progesterone—uterine cancer	0.00481	0.0187	CcSEcCtD
Carfilzomib—PSMB2—mammalian vulva—uterine cancer	0.00475	0.0177	CbGeAlD
Carfilzomib—Hypercalcaemia—Medroxyprogesterone Acetate—uterine cancer	0.00469	0.0182	CcSEcCtD
Carfilzomib—PSMB1—uterus—uterine cancer	0.00464	0.0172	CbGeAlD
Carfilzomib—PSMB2—uterus—uterine cancer	0.00453	0.0168	CbGeAlD
Carfilzomib—Neuritis—Medroxyprogesterone Acetate—uterine cancer	0.00436	0.017	CcSEcCtD
Carfilzomib—PSMB5—female gonad—uterine cancer	0.00434	0.0161	CbGeAlD
Carfilzomib—PSMB5—vagina—uterine cancer	0.00432	0.016	CbGeAlD
Carfilzomib—PSMB1—female reproductive system—uterine cancer	0.00417	0.0155	CbGeAlD
Carfilzomib—PSMB2—female reproductive system—uterine cancer	0.00407	0.0151	CbGeAlD
Carfilzomib—PSMB1—female gonad—uterine cancer	0.00379	0.0141	CbGeAlD
Carfilzomib—PSMB1—vagina—uterine cancer	0.00377	0.014	CbGeAlD
Carfilzomib—Tumour lysis syndrome—Epirubicin—uterine cancer	0.00371	0.0144	CcSEcCtD
Carfilzomib—PSMB2—female gonad—uterine cancer	0.0037	0.0138	CbGeAlD
Carfilzomib—PSMB2—vagina—uterine cancer	0.00368	0.0137	CbGeAlD
Carfilzomib—Peripheral sensory neuropathy—Epirubicin—uterine cancer	0.00361	0.014	CcSEcCtD
Carfilzomib—Tumour lysis syndrome—Doxorubicin—uterine cancer	0.00343	0.0134	CcSEcCtD
Carfilzomib—Peripheral sensory neuropathy—Doxorubicin—uterine cancer	0.00334	0.013	CcSEcCtD
Carfilzomib—Multi-organ failure—Epirubicin—uterine cancer	0.00316	0.0123	CcSEcCtD
Carfilzomib—PSMB8—lymph node—uterine cancer	0.00316	0.0117	CbGeAlD
Carfilzomib—Multi-organ failure—Doxorubicin—uterine cancer	0.00292	0.0114	CcSEcCtD
Carfilzomib—Hepatic failure—Progesterone—uterine cancer	0.0029	0.0113	CcSEcCtD
Carfilzomib—Sepsis—Medroxyprogesterone Acetate—uterine cancer	0.00283	0.011	CcSEcCtD
Carfilzomib—PSMB5—lymph node—uterine cancer	0.00279	0.0104	CbGeAlD
Carfilzomib—Musculoskeletal chest pain—Epirubicin—uterine cancer	0.00266	0.0103	CcSEcCtD
Carfilzomib—Hepatic failure—Medroxyprogesterone Acetate—uterine cancer	0.00263	0.0102	CcSEcCtD
Carfilzomib—Pain in extremity—Progesterone—uterine cancer	0.00261	0.0101	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Medroxyprogesterone Acetate—uterine cancer	0.00261	0.0101	CcSEcCtD
Carfilzomib—PSMB8—Medrysone—Medroxyprogesterone Acetate—uterine cancer	0.00251	0.197	CbGdCrCtD
Carfilzomib—Musculoskeletal chest pain—Doxorubicin—uterine cancer	0.00246	0.00956	CcSEcCtD
Carfilzomib—PSMB1—lymph node—uterine cancer	0.00244	0.00906	CbGeAlD
Carfilzomib—Infection—Carboplatin—uterine cancer	0.00242	0.00943	CcSEcCtD
Carfilzomib—PSMB2—lymph node—uterine cancer	0.00238	0.00884	CbGeAlD
Carfilzomib—Pain in extremity—Medroxyprogesterone Acetate—uterine cancer	0.00236	0.00919	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Progesterone—uterine cancer	0.00235	0.00913	CcSEcCtD
Carfilzomib—Blood creatinine increased—Medroxyprogesterone Acetate—uterine cancer	0.00221	0.00861	CcSEcCtD
Carfilzomib—Sepsis—Dactinomycin—uterine cancer	0.0022	0.00857	CcSEcCtD
Carfilzomib—PSMB8—Medrysone—Progesterone—uterine cancer	0.00218	0.172	CbGdCrCtD
Carfilzomib—Hypokalaemia—Medroxyprogesterone Acetate—uterine cancer	0.00215	0.00836	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Progesterone—uterine cancer	0.00209	0.00815	CcSEcCtD
Carfilzomib—Pain—Carboplatin—uterine cancer	0.00209	0.00811	CcSEcCtD
Carfilzomib—Hepatic failure—Dactinomycin—uterine cancer	0.00205	0.00797	CcSEcCtD
Carfilzomib—Hyperglycaemia—Progesterone—uterine cancer	0.00203	0.00791	CcSEcCtD
Carfilzomib—Pneumonia—Progesterone—uterine cancer	0.00202	0.00786	CcSEcCtD
Carfilzomib—Lymphopenia—Epirubicin—uterine cancer	0.00201	0.00783	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Progesterone—uterine cancer	0.00197	0.00766	CcSEcCtD
Carfilzomib—PSMB8—Podofilox—Etoposide—uterine cancer	0.00197	0.155	CbGdCrCtD
Carfilzomib—Body temperature increased—Carboplatin—uterine cancer	0.00193	0.0075	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Medroxyprogesterone Acetate—uterine cancer	0.0019	0.00738	CcSEcCtD
Carfilzomib—Lymphopenia—Doxorubicin—uterine cancer	0.00186	0.00724	CcSEcCtD
Carfilzomib—Hyperglycaemia—Medroxyprogesterone Acetate—uterine cancer	0.00184	0.00716	CcSEcCtD
Carfilzomib—PSMB8—Fluorometholone—Medroxyprogesterone Acetate—uterine cancer	0.00181	0.143	CbGdCrCtD
Carfilzomib—Acute coronary syndrome—Medroxyprogesterone Acetate—uterine cancer	0.0018	0.00698	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Medroxyprogesterone Acetate—uterine cancer	0.00179	0.00694	CcSEcCtD
Carfilzomib—Oedema peripheral—Progesterone—uterine cancer	0.00178	0.00691	CcSEcCtD
Carfilzomib—Hypophosphataemia—Epirubicin—uterine cancer	0.00177	0.00689	CcSEcCtD
Carfilzomib—Cardiac disorder—Progesterone—uterine cancer	0.00167	0.00651	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Dactinomycin—uterine cancer	0.00166	0.00645	CcSEcCtD
Carfilzomib—Hypophosphataemia—Doxorubicin—uterine cancer	0.00164	0.00638	CcSEcCtD
Carfilzomib—Hypomagnesaemia—Epirubicin—uterine cancer	0.00162	0.00631	CcSEcCtD
Carfilzomib—Oedema peripheral—Medroxyprogesterone Acetate—uterine cancer	0.00161	0.00626	CcSEcCtD
Carfilzomib—Sepsis—Etoposide—uterine cancer	0.00159	0.0062	CcSEcCtD
Carfilzomib—Back pain—Progesterone—uterine cancer	0.00152	0.00591	CcSEcCtD
Carfilzomib—Cardiac disorder—Medroxyprogesterone Acetate—uterine cancer	0.00152	0.0059	CcSEcCtD
Carfilzomib—Muscle spasms—Progesterone—uterine cancer	0.00151	0.00587	CcSEcCtD
Carfilzomib—Hypomagnesaemia—Doxorubicin—uterine cancer	0.0015	0.00583	CcSEcCtD
Carfilzomib—Neutropenia—Dactinomycin—uterine cancer	0.00149	0.00579	CcSEcCtD
Carfilzomib—Hypercalcaemia—Epirubicin—uterine cancer	0.00148	0.00577	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Etoposide—uterine cancer	0.00147	0.00572	CcSEcCtD
Carfilzomib—Chills—Medroxyprogesterone Acetate—uterine cancer	0.00147	0.0057	CcSEcCtD
Carfilzomib—Anaemia—Progesterone—uterine cancer	0.00145	0.00564	CcSEcCtD
Carfilzomib—Pneumonia—Dactinomycin—uterine cancer	0.00143	0.00556	CcSEcCtD
Carfilzomib—PSMB8—Testosterone Propionate—Medroxyprogesterone Acetate—uterine cancer	0.0014	0.11	CbGdCrCtD
Carfilzomib—Neuritis—Epirubicin—uterine cancer	0.00138	0.00537	CcSEcCtD
Carfilzomib—Back pain—Medroxyprogesterone Acetate—uterine cancer	0.00138	0.00535	CcSEcCtD
Carfilzomib—Hypercalcaemia—Doxorubicin—uterine cancer	0.00137	0.00533	CcSEcCtD
Carfilzomib—Cough—Progesterone—uterine cancer	0.00137	0.00533	CcSEcCtD
Carfilzomib—Muscle spasms—Medroxyprogesterone Acetate—uterine cancer	0.00137	0.00532	CcSEcCtD
Carfilzomib—Hypertension—Progesterone—uterine cancer	0.00136	0.00527	CcSEcCtD
Carfilzomib—Arthralgia—Progesterone—uterine cancer	0.00134	0.0052	CcSEcCtD
Carfilzomib—Anaemia—Medroxyprogesterone Acetate—uterine cancer	0.00132	0.00511	CcSEcCtD
Carfilzomib—Neuritis—Doxorubicin—uterine cancer	0.00128	0.00496	CcSEcCtD
Carfilzomib—Infection—Progesterone—uterine cancer	0.00127	0.00495	CcSEcCtD
Carfilzomib—Cardiac arrest—Etoposide—uterine cancer	0.00127	0.00493	CcSEcCtD
Carfilzomib—Anorexia—Progesterone—uterine cancer	0.00122	0.00475	CcSEcCtD
Carfilzomib—PSMB8—Testosterone Propionate—Progesterone—uterine cancer	0.00122	0.0957	CbGdCrCtD
Carfilzomib—Arthralgia—Medroxyprogesterone Acetate—uterine cancer	0.00121	0.00471	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Progesterone—uterine cancer	0.00117	0.00454	CcSEcCtD
Carfilzomib—Insomnia—Progesterone—uterine cancer	0.00116	0.00451	CcSEcCtD
Carfilzomib—Infection—Medroxyprogesterone Acetate—uterine cancer	0.00115	0.00449	CcSEcCtD
Carfilzomib—Chills—Dactinomycin—uterine cancer	0.00114	0.00445	CcSEcCtD
Carfilzomib—Dyspnoea—Progesterone—uterine cancer	0.00114	0.00444	CcSEcCtD
Carfilzomib—Thrombocytopenia—Medroxyprogesterone Acetate—uterine cancer	0.00114	0.00442	CcSEcCtD
Carfilzomib—Decreased appetite—Progesterone—uterine cancer	0.00111	0.00433	CcSEcCtD
Carfilzomib—Anorexia—Medroxyprogesterone Acetate—uterine cancer	0.00111	0.0043	CcSEcCtD
Carfilzomib—Fatigue—Progesterone—uterine cancer	0.00111	0.0043	CcSEcCtD
Carfilzomib—Pain—Progesterone—uterine cancer	0.0011	0.00426	CcSEcCtD
Carfilzomib—Constipation—Progesterone—uterine cancer	0.0011	0.00426	CcSEcCtD
Carfilzomib—Neutropenia—Etoposide—uterine cancer	0.00108	0.00419	CcSEcCtD
Carfilzomib—ABCB1—myometrium—uterine cancer	0.00107	0.00396	CbGeAlD
Carfilzomib—Musculoskeletal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.00106	0.00411	CcSEcCtD
Carfilzomib—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.00105	0.00408	CcSEcCtD
Carfilzomib—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.00104	0.00403	CcSEcCtD
Carfilzomib—Pneumonia—Etoposide—uterine cancer	0.00103	0.00402	CcSEcCtD
Carfilzomib—Anaemia—Dactinomycin—uterine cancer	0.00103	0.00399	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Etoposide—uterine cancer	0.00101	0.00394	CcSEcCtD
Carfilzomib—Body temperature increased—Progesterone—uterine cancer	0.00101	0.00394	CcSEcCtD
Carfilzomib—Renal failure—Etoposide—uterine cancer	0.00101	0.00393	CcSEcCtD
Carfilzomib—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.00101	0.00393	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Etoposide—uterine cancer	0.00101	0.00392	CcSEcCtD
Carfilzomib—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.001	0.00389	CcSEcCtD
Carfilzomib—Leukopenia—Dactinomycin—uterine cancer	0.000994	0.00386	CcSEcCtD
Carfilzomib—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.000993	0.00386	CcSEcCtD
Carfilzomib—Asthenia—Progesterone—uterine cancer	0.00092	0.00358	CcSEcCtD
Carfilzomib—Hypoaesthesia—Etoposide—uterine cancer	0.000918	0.00357	CcSEcCtD
Carfilzomib—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000918	0.00357	CcSEcCtD
Carfilzomib—PSMB8—Norethindrone—Progesterone—uterine cancer	0.000912	0.0717	CbGdCrCtD
Carfilzomib—Infection—Dactinomycin—uterine cancer	0.0009	0.0035	CcSEcCtD
Carfilzomib—Sepsis—Epirubicin—uterine cancer	0.000894	0.00348	CcSEcCtD
Carfilzomib—Thrombocytopenia—Dactinomycin—uterine cancer	0.000887	0.00345	CcSEcCtD
Carfilzomib—Diarrhoea—Progesterone—uterine cancer	0.000877	0.00341	CcSEcCtD
Carfilzomib—Anorexia—Dactinomycin—uterine cancer	0.000864	0.00336	CcSEcCtD
Carfilzomib—Cardiac disorder—Etoposide—uterine cancer	0.000857	0.00333	CcSEcCtD
Carfilzomib—Dizziness—Progesterone—uterine cancer	0.000848	0.0033	CcSEcCtD
Carfilzomib—ABCB1—epithelium—uterine cancer	0.000837	0.00311	CbGeAlD
Carfilzomib—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000833	0.00324	CcSEcCtD
Carfilzomib—Hepatic failure—Epirubicin—uterine cancer	0.000832	0.00324	CcSEcCtD
Carfilzomib—ABCB1—uterine cervix—uterine cancer	0.00083	0.00308	CbGeAlD
Carfilzomib—Chills—Etoposide—uterine cancer	0.000828	0.00322	CcSEcCtD
Carfilzomib—Sepsis—Doxorubicin—uterine cancer	0.000827	0.00322	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.000825	0.00321	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Epirubicin—uterine cancer	0.000825	0.00321	CcSEcCtD
Carfilzomib—Vomiting—Progesterone—uterine cancer	0.000815	0.00317	CcSEcCtD
Carfilzomib—Renal failure acute—Epirubicin—uterine cancer	0.00081	0.00315	CcSEcCtD
Carfilzomib—Headache—Progesterone—uterine cancer	0.000803	0.00312	CcSEcCtD
Carfilzomib—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000795	0.00309	CcSEcCtD
Carfilzomib—ABCB1—decidua—uterine cancer	0.000791	0.00294	CbGeAlD
Carfilzomib—Decreased appetite—Dactinomycin—uterine cancer	0.000788	0.00306	CcSEcCtD
Carfilzomib—Fatigue—Dactinomycin—uterine cancer	0.000781	0.00304	CcSEcCtD
Carfilzomib—Back pain—Etoposide—uterine cancer	0.000777	0.00302	CcSEcCtD
Carfilzomib—ABCB1—renal system—uterine cancer	0.000776	0.00288	CbGeAlD
Carfilzomib—Pain—Dactinomycin—uterine cancer	0.000775	0.00301	CcSEcCtD
Carfilzomib—Muscle spasms—Etoposide—uterine cancer	0.000772	0.003	CcSEcCtD
Carfilzomib—Hepatic failure—Doxorubicin—uterine cancer	0.00077	0.00299	CcSEcCtD
Carfilzomib—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000768	0.00299	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Doxorubicin—uterine cancer	0.000763	0.00297	CcSEcCtD
Carfilzomib—Nausea—Progesterone—uterine cancer	0.000761	0.00296	CcSEcCtD
Carfilzomib—Hyponatraemia—Epirubicin—uterine cancer	0.000751	0.00292	CcSEcCtD
Carfilzomib—ABCB1—endometrium—uterine cancer	0.00075	0.00279	CbGeAlD
Carfilzomib—Renal failure acute—Doxorubicin—uterine cancer	0.000749	0.00291	CcSEcCtD
Carfilzomib—Pain in extremity—Epirubicin—uterine cancer	0.000748	0.00291	CcSEcCtD
Carfilzomib—Anaemia—Etoposide—uterine cancer	0.000743	0.00289	CcSEcCtD
Carfilzomib—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000739	0.00287	CcSEcCtD
Carfilzomib—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000728	0.00283	CcSEcCtD
Carfilzomib—ABCB1—mammalian vulva—uterine cancer	0.000726	0.0027	CbGeAlD
Carfilzomib—PSMB8—Levonorgestrel—Progesterone—uterine cancer	0.000725	0.057	CbGdCrCtD
Carfilzomib—Leukopenia—Etoposide—uterine cancer	0.000719	0.0028	CcSEcCtD
Carfilzomib—Body temperature increased—Dactinomycin—uterine cancer	0.000716	0.00278	CcSEcCtD
Carfilzomib—Cardiac arrest—Epirubicin—uterine cancer	0.000711	0.00276	CcSEcCtD
Carfilzomib—Cough—Etoposide—uterine cancer	0.000701	0.00273	CcSEcCtD
Carfilzomib—Blood creatinine increased—Epirubicin—uterine cancer	0.000701	0.00272	CcSEcCtD
Carfilzomib—Hyponatraemia—Doxorubicin—uterine cancer	0.000695	0.0027	CcSEcCtD
Carfilzomib—Hypertension—Etoposide—uterine cancer	0.000694	0.0027	CcSEcCtD
Carfilzomib—Pain in extremity—Doxorubicin—uterine cancer	0.000692	0.00269	CcSEcCtD
Carfilzomib—ABCB1—uterus—uterine cancer	0.000692	0.00257	CbGeAlD
Carfilzomib—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.00069	0.00268	CcSEcCtD
Carfilzomib—Hypokalaemia—Epirubicin—uterine cancer	0.000681	0.00265	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.000673	0.00262	CcSEcCtD
Carfilzomib—Cardiac arrest—Doxorubicin—uterine cancer	0.000658	0.00256	CcSEcCtD
Carfilzomib—Infection—Etoposide—uterine cancer	0.000651	0.00253	CcSEcCtD
Carfilzomib—Asthenia—Dactinomycin—uterine cancer	0.00065	0.00253	CcSEcCtD
Carfilzomib—Blood creatinine increased—Doxorubicin—uterine cancer	0.000648	0.00252	CcSEcCtD
Carfilzomib—Thrombocytopenia—Etoposide—uterine cancer	0.000642	0.0025	CcSEcCtD
Carfilzomib—Hypokalaemia—Doxorubicin—uterine cancer	0.00063	0.00245	CcSEcCtD
Carfilzomib—Anorexia—Etoposide—uterine cancer	0.000625	0.00243	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.000623	0.00242	CcSEcCtD
Carfilzomib—ABCB1—female reproductive system—uterine cancer	0.000622	0.00231	CbGeAlD
Carfilzomib—Diarrhoea—Dactinomycin—uterine cancer	0.00062	0.00241	CcSEcCtD
Carfilzomib—Neutropenia—Epirubicin—uterine cancer	0.000604	0.00235	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000601	0.00234	CcSEcCtD
Carfilzomib—Dyspnoea—Etoposide—uterine cancer	0.000585	0.00227	CcSEcCtD
Carfilzomib—Hyperglycaemia—Epirubicin—uterine cancer	0.000583	0.00227	CcSEcCtD
Carfilzomib—Pneumonia—Epirubicin—uterine cancer	0.00058	0.00225	CcSEcCtD
Carfilzomib—Vomiting—Dactinomycin—uterine cancer	0.000576	0.00224	CcSEcCtD
Carfilzomib—Decreased appetite—Etoposide—uterine cancer	0.00057	0.00222	CcSEcCtD
Carfilzomib—Renal failure—Epirubicin—uterine cancer	0.000567	0.0022	CcSEcCtD
Carfilzomib—ABCB1—female gonad—uterine cancer	0.000566	0.0021	CbGeAlD
Carfilzomib—Fatigue—Etoposide—uterine cancer	0.000565	0.0022	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Epirubicin—uterine cancer	0.000565	0.0022	CcSEcCtD
Carfilzomib—ABCB1—vagina—uterine cancer	0.000562	0.00209	CbGeAlD
Carfilzomib—Pain—Etoposide—uterine cancer	0.000561	0.00218	CcSEcCtD
Carfilzomib—Constipation—Etoposide—uterine cancer	0.000561	0.00218	CcSEcCtD
Carfilzomib—Neutropenia—Doxorubicin—uterine cancer	0.000559	0.00217	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000556	0.00216	CcSEcCtD
Carfilzomib—Hyperglycaemia—Doxorubicin—uterine cancer	0.000539	0.0021	CcSEcCtD
Carfilzomib—Nausea—Dactinomycin—uterine cancer	0.000538	0.00209	CcSEcCtD
Carfilzomib—Pneumonia—Doxorubicin—uterine cancer	0.000536	0.00209	CcSEcCtD
Carfilzomib—Renal failure—Doxorubicin—uterine cancer	0.000524	0.00204	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Doxorubicin—uterine cancer	0.000523	0.00203	CcSEcCtD
Carfilzomib—Body temperature increased—Etoposide—uterine cancer	0.000518	0.00202	CcSEcCtD
Carfilzomib—Hypoaesthesia—Epirubicin—uterine cancer	0.000515	0.002	CcSEcCtD
Carfilzomib—Oedema peripheral—Epirubicin—uterine cancer	0.00051	0.00198	CcSEcCtD
Carfilzomib—Cardiac disorder—Epirubicin—uterine cancer	0.00048	0.00187	CcSEcCtD
Carfilzomib—Hypoaesthesia—Doxorubicin—uterine cancer	0.000476	0.00185	CcSEcCtD
Carfilzomib—Oedema peripheral—Doxorubicin—uterine cancer	0.000472	0.00183	CcSEcCtD
Carfilzomib—Asthenia—Etoposide—uterine cancer	0.00047	0.00183	CcSEcCtD
Carfilzomib—Chills—Epirubicin—uterine cancer	0.000464	0.0018	CcSEcCtD
Carfilzomib—Diarrhoea—Etoposide—uterine cancer	0.000449	0.00174	CcSEcCtD
Carfilzomib—Cardiac disorder—Doxorubicin—uterine cancer	0.000444	0.00173	CcSEcCtD
Carfilzomib—Back pain—Epirubicin—uterine cancer	0.000436	0.00169	CcSEcCtD
Carfilzomib—Dizziness—Etoposide—uterine cancer	0.000434	0.00169	CcSEcCtD
Carfilzomib—Muscle spasms—Epirubicin—uterine cancer	0.000433	0.00168	CcSEcCtD
Carfilzomib—Chills—Doxorubicin—uterine cancer	0.00043	0.00167	CcSEcCtD
Carfilzomib—Vomiting—Etoposide—uterine cancer	0.000417	0.00162	CcSEcCtD
Carfilzomib—Anaemia—Epirubicin—uterine cancer	0.000416	0.00162	CcSEcCtD
Carfilzomib—Headache—Etoposide—uterine cancer	0.000411	0.0016	CcSEcCtD
Carfilzomib—Leukopenia—Epirubicin—uterine cancer	0.000403	0.00157	CcSEcCtD
Carfilzomib—Back pain—Doxorubicin—uterine cancer	0.000403	0.00157	CcSEcCtD
Carfilzomib—Muscle spasms—Doxorubicin—uterine cancer	0.000401	0.00156	CcSEcCtD
Carfilzomib—Cough—Epirubicin—uterine cancer	0.000393	0.00153	CcSEcCtD
Carfilzomib—Nausea—Etoposide—uterine cancer	0.000389	0.00151	CcSEcCtD
Carfilzomib—Hypertension—Epirubicin—uterine cancer	0.000389	0.00151	CcSEcCtD
Carfilzomib—Anaemia—Doxorubicin—uterine cancer	0.000385	0.0015	CcSEcCtD
Carfilzomib—Arthralgia—Epirubicin—uterine cancer	0.000383	0.00149	CcSEcCtD
Carfilzomib—Leukopenia—Doxorubicin—uterine cancer	0.000373	0.00145	CcSEcCtD
Carfilzomib—Infection—Epirubicin—uterine cancer	0.000365	0.00142	CcSEcCtD
Carfilzomib—ABCB1—lymph node—uterine cancer	0.000364	0.00135	CbGeAlD
Carfilzomib—Cough—Doxorubicin—uterine cancer	0.000364	0.00141	CcSEcCtD
Carfilzomib—Thrombocytopenia—Epirubicin—uterine cancer	0.00036	0.0014	CcSEcCtD
Carfilzomib—Hypertension—Doxorubicin—uterine cancer	0.00036	0.0014	CcSEcCtD
Carfilzomib—Arthralgia—Doxorubicin—uterine cancer	0.000355	0.00138	CcSEcCtD
Carfilzomib—Anorexia—Epirubicin—uterine cancer	0.00035	0.00136	CcSEcCtD
Carfilzomib—Infection—Doxorubicin—uterine cancer	0.000338	0.00131	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000335	0.0013	CcSEcCtD
Carfilzomib—Thrombocytopenia—Doxorubicin—uterine cancer	0.000333	0.00129	CcSEcCtD
Carfilzomib—Insomnia—Epirubicin—uterine cancer	0.000332	0.00129	CcSEcCtD
Carfilzomib—Dyspnoea—Epirubicin—uterine cancer	0.000328	0.00127	CcSEcCtD
Carfilzomib—Anorexia—Doxorubicin—uterine cancer	0.000324	0.00126	CcSEcCtD
Carfilzomib—Decreased appetite—Epirubicin—uterine cancer	0.00032	0.00124	CcSEcCtD
Carfilzomib—Fatigue—Epirubicin—uterine cancer	0.000317	0.00123	CcSEcCtD
Carfilzomib—Pain—Epirubicin—uterine cancer	0.000314	0.00122	CcSEcCtD
Carfilzomib—Constipation—Epirubicin—uterine cancer	0.000314	0.00122	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.00031	0.0012	CcSEcCtD
Carfilzomib—Insomnia—Doxorubicin—uterine cancer	0.000308	0.0012	CcSEcCtD
Carfilzomib—Dyspnoea—Doxorubicin—uterine cancer	0.000303	0.00118	CcSEcCtD
Carfilzomib—Decreased appetite—Doxorubicin—uterine cancer	0.000296	0.00115	CcSEcCtD
Carfilzomib—Fatigue—Doxorubicin—uterine cancer	0.000293	0.00114	CcSEcCtD
Carfilzomib—Pain—Doxorubicin—uterine cancer	0.000291	0.00113	CcSEcCtD
Carfilzomib—Constipation—Doxorubicin—uterine cancer	0.000291	0.00113	CcSEcCtD
Carfilzomib—Body temperature increased—Epirubicin—uterine cancer	0.000291	0.00113	CcSEcCtD
Carfilzomib—Body temperature increased—Doxorubicin—uterine cancer	0.000269	0.00105	CcSEcCtD
Carfilzomib—Asthenia—Epirubicin—uterine cancer	0.000264	0.00103	CcSEcCtD
Carfilzomib—Diarrhoea—Epirubicin—uterine cancer	0.000251	0.000978	CcSEcCtD
Carfilzomib—Asthenia—Doxorubicin—uterine cancer	0.000244	0.000949	CcSEcCtD
Carfilzomib—Dizziness—Epirubicin—uterine cancer	0.000243	0.000945	CcSEcCtD
Carfilzomib—Vomiting—Epirubicin—uterine cancer	0.000234	0.000909	CcSEcCtD
Carfilzomib—Diarrhoea—Doxorubicin—uterine cancer	0.000233	0.000905	CcSEcCtD
Carfilzomib—Headache—Epirubicin—uterine cancer	0.00023	0.000895	CcSEcCtD
Carfilzomib—Dizziness—Doxorubicin—uterine cancer	0.000225	0.000874	CcSEcCtD
Carfilzomib—Nausea—Epirubicin—uterine cancer	0.000218	0.000849	CcSEcCtD
Carfilzomib—Vomiting—Doxorubicin—uterine cancer	0.000216	0.000841	CcSEcCtD
Carfilzomib—Headache—Doxorubicin—uterine cancer	0.000213	0.000828	CcSEcCtD
Carfilzomib—Nausea—Doxorubicin—uterine cancer	0.000202	0.000785	CcSEcCtD
Carfilzomib—PSMB8—Signaling Pathways—FGFR2—uterine cancer	5.55e-05	0.000162	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—NRAS—uterine cancer	5.49e-05	0.00016	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—ERBB2—uterine cancer	5.47e-05	0.00016	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—ERBB2—uterine cancer	5.47e-05	0.00016	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—ERBB2—uterine cancer	5.47e-05	0.00016	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—NRAS—uterine cancer	5.46e-05	0.00016	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	5.44e-05	0.000159	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—PIK3CA—uterine cancer	5.42e-05	0.000158	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—PIK3CA—uterine cancer	5.42e-05	0.000158	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—PIK3CA—uterine cancer	5.42e-05	0.000158	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—EP300—uterine cancer	5.42e-05	0.000158	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—EP300—uterine cancer	5.39e-05	0.000158	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—ERBB2—uterine cancer	5.39e-05	0.000157	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—PIK3CA—uterine cancer	5.35e-05	0.000156	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	5.15e-05	0.000151	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—NRAS—uterine cancer	5.07e-05	0.000148	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CDKN1B—uterine cancer	5.06e-05	0.000148	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CDKN1B—uterine cancer	5.06e-05	0.000148	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CDKN1B—uterine cancer	5.06e-05	0.000148	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—ERBB2—uterine cancer	5.05e-05	0.000147	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—ERBB2—uterine cancer	5.05e-05	0.000147	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—ERBB2—uterine cancer	5.05e-05	0.000147	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—NRAS—uterine cancer	5.04e-05	0.000147	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—HRAS—uterine cancer	5.02e-05	0.000147	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—HRAS—uterine cancer	5.02e-05	0.000147	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—HRAS—uterine cancer	5.02e-05	0.000147	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—CDKN1B—uterine cancer	4.99e-05	0.000146	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—ERBB2—uterine cancer	4.98e-05	0.000145	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—HRAS—uterine cancer	4.95e-05	0.000145	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—ESR1—uterine cancer	4.82e-05	0.000141	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—ESR1—uterine cancer	4.82e-05	0.000141	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—ESR1—uterine cancer	4.82e-05	0.000141	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CTNNB1—uterine cancer	4.78e-05	0.00014	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CTNNB1—uterine cancer	4.78e-05	0.00014	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CTNNB1—uterine cancer	4.78e-05	0.00014	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—PTEN—uterine cancer	4.76e-05	0.000139	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—ESR1—uterine cancer	4.75e-05	0.000139	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—PTEN—uterine cancer	4.74e-05	0.000138	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—KRAS—uterine cancer	4.73e-05	0.000138	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—CTNNB1—uterine cancer	4.72e-05	0.000138	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—KRAS—uterine cancer	4.7e-05	0.000137	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—CDKN1B—uterine cancer	4.68e-05	0.000137	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—CDKN1B—uterine cancer	4.68e-05	0.000137	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—CDKN1B—uterine cancer	4.68e-05	0.000137	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—ERBB2—uterine cancer	4.67e-05	0.000136	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—PTEN—uterine cancer	4.66e-05	0.000136	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—PTEN—uterine cancer	4.66e-05	0.000136	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—PTEN—uterine cancer	4.66e-05	0.000136	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—ERBB2—uterine cancer	4.64e-05	0.000136	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—CDKN1B—uterine cancer	4.61e-05	0.000135	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—PTEN—uterine cancer	4.6e-05	0.000134	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—EP300—uterine cancer	4.54e-05	0.000133	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—POLD1—uterine cancer	4.52e-05	0.000132	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—EP300—uterine cancer	4.52e-05	0.000132	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—EP300—uterine cancer	4.45e-05	0.00013	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—EP300—uterine cancer	4.45e-05	0.00013	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—EP300—uterine cancer	4.45e-05	0.00013	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—AKT1—uterine cancer	4.43e-05	0.000129	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—AKT1—uterine cancer	4.43e-05	0.000129	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—AKT1—uterine cancer	4.43e-05	0.000129	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CXCL8—uterine cancer	4.42e-05	0.000129	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—CTNNB1—uterine cancer	4.42e-05	0.000129	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—CTNNB1—uterine cancer	4.42e-05	0.000129	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—CTNNB1—uterine cancer	4.42e-05	0.000129	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CXCL8—uterine cancer	4.4e-05	0.000129	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—EP300—uterine cancer	4.38e-05	0.000128	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	4.38e-05	0.000128	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—AKT1—uterine cancer	4.37e-05	0.000128	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—KRAS—uterine cancer	4.36e-05	0.000127	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—CTNNB1—uterine cancer	4.36e-05	0.000127	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—KRAS—uterine cancer	4.34e-05	0.000127	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—PIK3CA—uterine cancer	4.34e-05	0.000127	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CDKN1B—uterine cancer	4.32e-05	0.000126	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—PIK3CA—uterine cancer	4.32e-05	0.000126	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—PTEN—uterine cancer	4.31e-05	0.000126	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—PTEN—uterine cancer	4.31e-05	0.000126	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—PTEN—uterine cancer	4.31e-05	0.000126	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CDKN1B—uterine cancer	4.3e-05	0.000126	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—PTEN—uterine cancer	4.24e-05	0.000124	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCL2—uterine cancer	4.24e-05	0.000124	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCL2—uterine cancer	4.24e-05	0.000124	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCL2—uterine cancer	4.24e-05	0.000124	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AKR1C1—uterine cancer	4.23e-05	0.000124	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCL2—uterine cancer	4.18e-05	0.000122	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—NRAS—uterine cancer	4.16e-05	0.000122	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—NRAS—uterine cancer	4.16e-05	0.000122	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—NRAS—uterine cancer	4.16e-05	0.000122	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—EP300—uterine cancer	4.11e-05	0.00012	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—EP300—uterine cancer	4.11e-05	0.00012	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—EP300—uterine cancer	4.11e-05	0.00012	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—NRAS—uterine cancer	4.1e-05	0.00012	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CTNNB1—uterine cancer	4.08e-05	0.000119	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CTNNB1—uterine cancer	4.06e-05	0.000119	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—EP300—uterine cancer	4.05e-05	0.000118	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	4.02e-05	0.000118	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—HRAS—uterine cancer	4.02e-05	0.000117	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—PIK3CA—uterine cancer	4.01e-05	0.000117	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—HRAS—uterine cancer	4e-05	0.000117	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—PIK3CA—uterine cancer	3.99e-05	0.000117	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—PTEN—uterine cancer	3.98e-05	0.000116	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—PTEN—uterine cancer	3.96e-05	0.000116	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	3.89e-05	0.000114	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—NRAS—uterine cancer	3.84e-05	0.000112	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—NRAS—uterine cancer	3.84e-05	0.000112	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—NRAS—uterine cancer	3.84e-05	0.000112	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—EP300—uterine cancer	3.79e-05	0.000111	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—NRAS—uterine cancer	3.79e-05	0.000111	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—EP300—uterine cancer	3.78e-05	0.00011	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—RRM2—uterine cancer	3.77e-05	0.00011	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—HRAS—uterine cancer	3.71e-05	0.000108	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—HRAS—uterine cancer	3.69e-05	0.000108	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—DCN—uterine cancer	3.66e-05	0.000107	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PTEN—uterine cancer	3.61e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PTEN—uterine cancer	3.61e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PTEN—uterine cancer	3.61e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—VEGFA—uterine cancer	3.59e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—KRAS—uterine cancer	3.58e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—KRAS—uterine cancer	3.58e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—KRAS—uterine cancer	3.58e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—VEGFA—uterine cancer	3.58e-05	0.000104	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PTEN—uterine cancer	3.56e-05	0.000104	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—NRAS—uterine cancer	3.55e-05	0.000104	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—AKT1—uterine cancer	3.55e-05	0.000104	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—ERBB2—uterine cancer	3.54e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—ERBB2—uterine cancer	3.54e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—ERBB2—uterine cancer	3.54e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—NRAS—uterine cancer	3.53e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—KRAS—uterine cancer	3.53e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—AKT1—uterine cancer	3.53e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB10—Gene Expression—AKT1—uterine cancer	3.53e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—AKT1—uterine cancer	3.51e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—ERBB2—uterine cancer	3.49e-05	0.000102	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP11A1—uterine cancer	3.45e-05	0.000101	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—EP300—uterine cancer	3.44e-05	0.0001	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—EP300—uterine cancer	3.44e-05	0.0001	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—EP300—uterine cancer	3.44e-05	0.0001	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—EP300—uterine cancer	3.39e-05	9.9e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—PIK3CA—uterine cancer	3.36e-05	9.81e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CXCL8—uterine cancer	3.35e-05	9.79e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CXCL8—uterine cancer	3.35e-05	9.79e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CXCL8—uterine cancer	3.35e-05	9.79e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—PIK3CA—uterine cancer	3.34e-05	9.76e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—KRAS—uterine cancer	3.31e-05	9.66e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—KRAS—uterine cancer	3.31e-05	9.66e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—KRAS—uterine cancer	3.31e-05	9.66e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CXCL8—uterine cancer	3.31e-05	9.66e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—PIK3CA—uterine cancer	3.29e-05	9.61e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—PIK3CA—uterine cancer	3.29e-05	9.61e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—PIK3CA—uterine cancer	3.29e-05	9.61e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	3.29e-05	9.6e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CDKN1B—uterine cancer	3.27e-05	9.57e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CDKN1B—uterine cancer	3.27e-05	9.57e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CDKN1B—uterine cancer	3.27e-05	9.57e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—AKT1—uterine cancer	3.27e-05	9.56e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—KRAS—uterine cancer	3.26e-05	9.52e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—AKT1—uterine cancer	3.26e-05	9.52e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AKR1C3—uterine cancer	3.26e-05	9.52e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—PIK3CA—uterine cancer	3.24e-05	9.47e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CDKN1B—uterine cancer	3.23e-05	9.43e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CTNNB1—uterine cancer	3.09e-05	9.04e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CTNNB1—uterine cancer	3.09e-05	9.04e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CTNNB1—uterine cancer	3.09e-05	9.04e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—KRAS—uterine cancer	3.06e-05	8.92e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CTNNB1—uterine cancer	3.05e-05	8.91e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—HRAS—uterine cancer	3.04e-05	8.89e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—HRAS—uterine cancer	3.04e-05	8.89e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—HRAS—uterine cancer	3.04e-05	8.89e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—KRAS—uterine cancer	3.04e-05	8.88e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—PIK3CA—uterine cancer	3.04e-05	8.87e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—PIK3CA—uterine cancer	3.04e-05	8.87e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—PIK3CA—uterine cancer	3.04e-05	8.87e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PTEN—uterine cancer	3.02e-05	8.81e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PTEN—uterine cancer	3.02e-05	8.81e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PTEN—uterine cancer	3.02e-05	8.81e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—HRAS—uterine cancer	3e-05	8.77e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—PIK3CA—uterine cancer	2.99e-05	8.75e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PTEN—uterine cancer	2.97e-05	8.68e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—EP300—uterine cancer	2.88e-05	8.4e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—EP300—uterine cancer	2.88e-05	8.4e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—EP300—uterine cancer	2.88e-05	8.4e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—EP300—uterine cancer	2.83e-05	8.28e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—HRAS—uterine cancer	2.81e-05	8.21e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—HRAS—uterine cancer	2.81e-05	8.21e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—HRAS—uterine cancer	2.81e-05	8.21e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—PIK3CA—uterine cancer	2.81e-05	8.2e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—PIK3CA—uterine cancer	2.79e-05	8.16e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—HRAS—uterine cancer	2.77e-05	8.09e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—AKT1—uterine cancer	2.74e-05	8.01e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—AKT1—uterine cancer	2.73e-05	7.97e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—VEGFA—uterine cancer	2.72e-05	7.96e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—VEGFA—uterine cancer	2.72e-05	7.96e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—VEGFA—uterine cancer	2.72e-05	7.96e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TP53—uterine cancer	2.72e-05	7.93e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TP53—uterine cancer	2.7e-05	7.89e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NRAS—uterine cancer	2.69e-05	7.86e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NRAS—uterine cancer	2.69e-05	7.86e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NRAS—uterine cancer	2.69e-05	7.86e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—AKT1—uterine cancer	2.69e-05	7.85e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—AKT1—uterine cancer	2.69e-05	7.85e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—AKT1—uterine cancer	2.69e-05	7.85e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—VEGFA—uterine cancer	2.68e-05	7.84e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—AKT1—uterine cancer	2.67e-05	7.81e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—AKT1—uterine cancer	2.67e-05	7.81e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—AKT1—uterine cancer	2.67e-05	7.81e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NRAS—uterine cancer	2.65e-05	7.75e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—AKT1—uterine cancer	2.65e-05	7.74e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—AKT1—uterine cancer	2.63e-05	7.7e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—HRAS—uterine cancer	2.6e-05	7.59e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—HRAS—uterine cancer	2.58e-05	7.55e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PIK3CA—uterine cancer	2.54e-05	7.43e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PIK3CA—uterine cancer	2.54e-05	7.43e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PIK3CA—uterine cancer	2.54e-05	7.43e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP19A1—uterine cancer	2.54e-05	7.41e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—STK11—uterine cancer	2.54e-05	7.41e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PIK3CA—uterine cancer	2.51e-05	7.33e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—AKT1—uterine cancer	2.48e-05	7.25e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—AKT1—uterine cancer	2.48e-05	7.25e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—AKT1—uterine cancer	2.48e-05	7.25e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—AKT1—uterine cancer	2.45e-05	7.15e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—KRAS—uterine cancer	2.32e-05	6.76e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—KRAS—uterine cancer	2.32e-05	6.76e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—KRAS—uterine cancer	2.32e-05	6.76e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—AKT1—uterine cancer	2.29e-05	6.7e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—KRAS—uterine cancer	2.28e-05	6.67e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—AKT1—uterine cancer	2.28e-05	6.67e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3CA—uterine cancer	2.13e-05	6.21e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3CA—uterine cancer	2.13e-05	6.21e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3CA—uterine cancer	2.13e-05	6.21e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CA—uterine cancer	2.1e-05	6.13e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—AKT1—uterine cancer	2.08e-05	6.07e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—AKT1—uterine cancer	2.08e-05	6.07e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—AKT1—uterine cancer	2.08e-05	6.07e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TP53—uterine cancer	2.06e-05	6.01e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TP53—uterine cancer	2.06e-05	6.01e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TP53—uterine cancer	2.06e-05	6.01e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—AKT1—uterine cancer	2.05e-05	5.98e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TP53—uterine cancer	2.03e-05	5.93e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—HRAS—uterine cancer	1.97e-05	5.75e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—HRAS—uterine cancer	1.97e-05	5.75e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—HRAS—uterine cancer	1.97e-05	5.75e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—HRAS—uterine cancer	1.94e-05	5.67e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—MTHFR—uterine cancer	1.91e-05	5.57e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—AKT1—uterine cancer	1.74e-05	5.08e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—AKT1—uterine cancer	1.74e-05	5.08e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—AKT1—uterine cancer	1.74e-05	5.08e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—AKT1—uterine cancer	1.71e-05	5e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PTEN—uterine cancer	1.06e-05	3.1e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—EP300—uterine cancer	1.01e-05	2.96e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CA—uterine cancer	7.48e-06	2.19e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AKT1—uterine cancer	6.11e-06	1.79e-05	CbGpPWpGaD
